OncoMatch/Clinical Trials/NCT05169112
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Is NCT05169112 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Lupron Depot for prostate cancer.
Treatment: Lupron Depot — Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation after recurrence is successful in less than half of these men and most of those die from their disease. Measures to prevent recurrence are an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Prior therapy
Must have received: radical prostatectomy — post-operative
within 16 weeks post-operative
Cannot have received: androgen deprivation therapy
previously received ADT
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify